Salutem Insights Ltd.

With our recent growth in followers, we'd like to welcome our new connections and highlight what Salutem Insights offers in the realm of Irish Market Access support. As the Irish experts in this field, we are the go-to company for support in navigating the complexities of the Irish reimbursement process. Discover how Salutem Insights can help you navigate the Irish healthcare landscape with our expertise and support. 👇 Watch the video here: https://lnkd.in/dPmJgNzZ #IrishMarketAccess #IrishHealthcare #Pharma #HealthEconomics #SalutemInsights #IrishReimbursementProcess

A doubling of clinical trial activity in Ireland: that is the objective set by Health Minister Stephen Donnelly. To that end, he has established the National Clinical Trials Oversight Group under the oversight of Donal Brennan, Professor of Gynaecological Oncology at University College Dublin (tinyurl.com/bdfy4ta4). Ireland thus joins a growing number of countries across Europe and beyond looking to increase their share of global clinical studies.   Donnelly commented: “Ireland is not attracting as many clinical trials as some other European countries. We need to do better for patients. I want to double the number of clinical trials taking place in Ireland. A strong clinical trial infrastructure can give patients access to treatments that deliver improved outcomes and, in some cases, can be lifesaving. I want to see Ireland aim for best in class globally in terms hosting more clinical trials, thereby increasing the number of people who can access and participate in clinical trials with the ultimate objective of achieving better patient outcomes.”   Brennan said: “There is now irrefutable evidence that increased research activity correlates with improved clinical outcomes across multiple healthcare systems, particularly when patients participate in clinical trials. I hope that this Group can work together to make Ireland a destination of choice for clinical trials, whereby patients can access new medicines and technologies in a safe, efficient, ethical and transparent fashion.”   The purpose of the new group is to ensure “a nationally coordinated approach to the management of clinical trials, from industry sponsored to academically led, to improve Ireland’s national clinical trials landscape and international reputation as a hub for clinical research. The ultimate ambition is to enhance and improve the efficiency of the Irish clinical trials landscape to drive further research and innovation which can lead to improved clinical outcomes.”   Among other tasks, the group will identify obstacles and challenges that sponsors face in conducting clinical research in Ireland and develop proposals to address these challenges. It will also “optimise the use of data pertaining to clinical trials with the view to collating a holistic viewpoint of the clinical trials landscape to enhance Department of Health policy decision making.”   From the industry’s perspective, one of the constraints on clinical trial activity may be the country’s relatively low reimbursement of new drugs. The latest EFPIA Patients WAIT Indicator Survey found that only 28% of new drugs were available in Ireland, compared with an EU average of 43%. It is envisaged that the National Clinical Trials Oversight Group will be operational for one year. It will be interesting to see how much progress can be made in that timeframe. #Ireland #clinicaltrials

We recently had a fantastic team day out at the Jameson Distillery Bow St., another Irish expert in its field—though perhaps a bit tastier! At Salutem Insights, we pride ourselves on the expertise and dedication of our team. Our customers not only value our skill and knowledge but also appreciate working with our genuinely great group of professionals. Our team's commitment to excellence and collaborative spirit is what sets us apart. Thank you to the team for being an integral part of the Salutem Insights success story.👏 #TeamSalutem #HealthcareExperts #IrishMarketAccess #IrishPharma #ProfessionalDevelopment #TeamBuilding

Another great session at IPHA Headquarters for the second of their Summer Leaders Lunches, organised by Yvonne (O' Toole) 🔑 𝐊𝐞𝐲 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐬𝐞𝐬𝐬𝐢𝐨𝐧:   1. Accelerating medicine development in Ireland: • It was fantastic to hear what IPHA are doing to accelerate medicine development, given that Ireland lags behind peer European countries in terms of attracting clinical trials. • Some of the reforms suggested by Killian MacDonald, Director of Commercial Operation in Gilead and lead of the Clinical Research Exchange Group in IPHA, were: 📝 Standardising clinical trial start-up requirements 👩⚕️ Appointing a permanent clinical research nurses in teaching hospitals 💰 Ring-fencing clinical trial funding • These reforms are necessary for Ireland to reach its potential in attracting clinical trials. • This potential was highlighted in a recent report by IQVIA Institute which noted that Ireland has high operational readiness and extra capacity for conducting clinical trials (see diagram above and link to report: Rethinking Clinical Trial Country Prioritization - IQVIA) https://lnkd.in/dMrqRjjg   2. Challenges to Securing Reimbursement of New Medicines in Ireland: • It was also great to hear from Duggan Caitriona, General Manager Amgen and the lead of the Market Access Forum in IPHA. • Caitriona highlighted the challenges to securing reimbursement of new medicines in Ireland, noting our long and arduous reimbursement process: 32/33 steps that take an average of 2.5 years. • IPHA and the market access community in Ireland eagerly await the publication of the Mazars report on reforms to the HSE’s Drug Pricing and Reimbursement Process, expected imminently. • This report is expected to include reforms around improving the process, increasing transparency, providing easier access, and supporting value for money.   👏 A great session into the work of the IPHA Market Access Advisory Forum (MAAF) and Clinical Trials Group.   📅 Looking forward to the last in this series on August 21st. #Pharma #ClinicalTrials #HealthcareInnovation #MarketAccess #IPHA #MedicinesDevelopment #ReimbursementProcess #HealthEconomics #SalutemInsights #HealthcareReform #CPD #Partnerships

Collaborating beyond classic country borders in order to share knowledge and pave the way in multiple ways towards market access. Accessus Health GmbH has the ambition to deliver the most efficient next-level support by combining EU HTA insights with country specific expertise from premium consultants throughout Europe, incl. HEBIAS. Feel free to discover yourself the partners involved and the tailor made services we deliver. 👉 www.euaccess.eu Accessus Health GmbH - CEMKA (France) - Cogentia Healthcare Consulting - EconMed Europe - Ecker Ecker GmbH - HEBIAS - MOAI Consulting - More Than Access (MTA) - Outcomes'10 - Salutem Insights Ltd. - SICOmed AG - Zealth - https://kwpc.at/ #ispor #HTA #innovation #pharma #MarketAccess

Delighted to be part of this partnership with 13 premier Market Access Consultancies, covering all major European Markets

New Partnership, New Horizons: Together, Supporting Pharma Across Europe in the Era of EU HTA Salutem Insights is thrilled to announce the launch of a new partnership with 13 premier Market Access Consultancies, covering all major European Markets. This collaboration aims to support pharmaceutical businesses in navigating the new EU HTA legislation, ensuring innovative medicines reach patients across Europe. Visit our new website to learn more about how we can help you gain market access: www.euaccess.eu Together, we're ready to support you in achieving success in the evolving European healthcare landscape. Zealth Ecker Ecker GmbH Cogentia Healthcare Consulting HEBIAS EconMed EuropeMOAI Consulting CEMKA (France) Accessus Health GmbH Outcomes'10 Krammer, Wrbka & Partner Consulting SICOmed #HTA #EUHTA #MarketAccess #Pharma #HealthcareInnovation #SalutemInsights

Zealth is extremely pleased to announce our partnership with 12 premier Market Access Consultancies covering all major European Markets. To learn more about the partnership, please visit: www.euaccess.eu We look forward to supporting our customers together with our partners to gain access for patients to innovative medicines. Ecker Ecker GmbH Salutem Insights Ltd. Cogentia Healthcare Consulting HEBIAS EconMed Europe MOAI Consulting CEMKA (France) Accessus Health GmbH Outcomes'10 More Than Access (MTA) Krammer, Wrbka & Partner Consulting, SICOmed. #HTA #GetReadyForEUHTA

Fantastic to hear from IPHA leaders Michael O Connell from Biogen UK & Ireland and IPHA President, and Eimear Caslin from GSK and Chair of the Communications Advisory and Advocacy Forum on the great work that IPHA does to promote the pharmaceutical industry nationally and internationally.

🌟 Highlights from the PMI Masterclass 🌟 Last week, our Managing Director, Sandra Redmond, had the honour of speaking at the PMI Masterclass, "From Drug Discovery to Dispensing," hosted by The Pharmaceutical Managers Institute and supported by Uniphar | Commercial. Sandra’s session, "Market Access 101" provided a unique perspective on the topic through her personal story. Sandra shared insights from her extensive experience in asthma research and submissions to the NCPE - National Centre for Pharmacoeconomics. She also brought the facts to life by discussing the real-life challenges of managing her son Liam's asthma. This personal narrative illustrated the critical Pricing Agreements and the Health (Pricing and Supply) Act 2013, highlighting their role in making essential medicines like salbutamol, montelukast, and Seretide® affordable and accessible. Sandra emphasised the reimbursement process for newer, more expensive asthma medications such as mepolizumab and dupilumab, underlining the importance of patient-centric healthcare. She also highlighted the significant role patient organisations, like the Asthma Society of Ireland, play in supporting families. 👉 For more insights from Sandra’s session, including her experiences and the impact of these healthcare frameworks, read the full article on our blog https://bit.ly/4cbHIEU. 👉To access the Asthma Society of Ireland's helpline ☎ 1800 44 54 64 or Whatsapp 086 059 0132. 👉To read the full report Easing the Economic Burden of Asthma, click here https://bit.ly/45B3HTq We look forward to continuing the conversation with all of our partners in the health ecosystem and advocating for patient access to life-saving medicines. #MarketAccess #Healthcare #AsthmaResearch #Pharmaceuticals #PMIMasterclass #SalutemInsights #PatientCentricCare